| Literature DB >> 34465636 |
Baurzhan Zhussupov1,2, Timur Saliev3, Gulya Sarybayeva4, Kuanysh Altynbekov5, Shynar Tanabayeva2, Sagat Altynbekov2, Gulnara Tuleshova4, Dainius Pavalkis4, Ildar Fakhradiyev6.
Abstract
BACKGROUND: This study aimed to analyze the demographic and epidemiological features of identified COVID-19 cases in Kazakhstan. STUDYEntities:
Keywords: COVID-19; Comorbidity; Coronavirus; Epidemiology; Mortality
Mesh:
Year: 2021 PMID: 34465636 PMCID: PMC8957677 DOI: 10.34172/jrhs.2021.52
Source DB: PubMed Journal: J Res Health Sci ISSN: 2228-7795
Demographic and clinical characteristics of COVID-19 cases
|
|
|
|
| Gender | ||
| Male | 2849 | 55.7 |
| Female | 2267 | 44.3 |
| Age (year) | ||
| <10 | 369 | 7.2 |
| 10-19 | 419 | 8.2 |
| 20-29 | 1496 | 29.2 |
| 30-39 | 1016 | 19.9 |
| 40-49 | 725 | 14.2 |
| 50-59 | 644 | 12.6 |
| 60-69 | 242 | 4.7 |
| Over 70 | 178 | 3.5 |
| Region (population in the study, total %) | ||
| Akmola region (736.2, 3.9%) | 129 | 2.5 |
| Aktobe region (883.6, 4.7%) | 288 | 5.6 |
| Alma-Ata's region (2059.1, 11.0%) | 242 | 4.7 |
| Atyrau region (647.4, 3.5%) | 53 | 1.0 |
| Eastern Kazakhstan region (1368.2, 7.3%) | 62 | 1.2 |
| Zhambyl region (1131, 6.1%) | 219 | 4.3 |
| Western Kazakhstan region (657.6, 3.5%) | 340 | 6.6 |
| Karaganda region (1376.6, 7.4%) | 333 | 6.5 |
| Kostanay region (867.9, 4.6%) | 84 | 1.6 |
| Kyzylorda Region (805.1, 4.3%) | 189 | 3.7 |
| Mangistau region (703, 3.8%) | 127 | 2.5 |
| Pavlodar region (752, 4.0%) | 152 | 3.0 |
| North-Kazakhstan region (547.7, 2.9%) | 35 | 0.7 |
| Turkestan region (2021.8, 10.8%) | 311 | 6.1 |
| Nur-Sultan city (1144.8, 6.1%) | 428 | 8.4 |
| Almaty city (1927.7, 10.3%) | 1844 | 36 |
| Shymkent (1042.2, 5.6%) | 280 | 5.5 |
| Residence | ||
| Urban | 4044 | 79.6 |
| Rural | 1037 | 20.4 |
| Symptoms during registration of the disease | ||
| Fever | 589 | 11.6 |
| Sore throat | 873 | 17.1 |
| Rhinorrhoea | 369 | 7.2 |
| Cough | 1063 | 20.8 |
| Muscle pain | 161 | 3.2 |
| Diarrhoea | 110 | 2.2 |
| Dyspnoea | 204 | 4.0 |
| Disease severity | ||
| Asymptomatic | 2074 | 40.9 |
| Mild | 1863 | 36.7 |
| Moderate | 1018 | 20.1 |
| Severe | 109 | 2.1 |
| Critical | 6 | 0.1 |
| Pregnancy | 78 | 3.4 |
| Co-morbidities | ||
| Cardiovascular disease | 285 | 2.6 |
| Hypertension | 380 | 7.4 |
| Immuno-deficiency | 7 | 0.1 |
| Diabetes | 128 | 2.5 |
| Obesity | 84 | 1.7 |
| Kidney disease | 100 | 2.0 |
| Liver disease | 61 | 1.2 |
| Respiratory disease | 230 | 4.6 |
| Neurological disease | 63 | 1.2 |
| Malignancy | 20 | 0.4 |
| Anemia | 205 | 4.0 |
| Allergy | 133 | 2.6 |
| Complications | ||
| Pneumonia | 932 | 18.9 |
| ARDS | 61 | 1.2 |
| Mechanical ventilation | 64 | 1.3 |
| Outcome | ||
| Died | 49 | 1.0 |
Figure 1Presence of COVID-19 symptoms at the time of registration in terms of gender and age
|
|
|
|
|
|
|
|
|
|
|
|
| |||||||||
| <10 | 369 | 87 | 29 | 33 | 17 | 46 | 4 | 9 | 3 |
| 10-19 | 419 | 120 | 29 | 64 | 31 | 59 | 4 | 5 | 7 |
| 20-29 | 1496 | 496 | 125 | 259 | 151 | 244 | 32 | 26 | 27 |
| 30-39 | 1016 | 388 | 122 | 205 | 77 | 219 | 40 | 29 | 28 |
| 40-49 | 725 | 282 | 100 | 131 | 41 | 178 | 34 | 14 | 29 |
| 50-59 | 644 | 269 | 107 | 107 | 33 | 180 | 20 | 18 | 36 |
| 60-69 | 242 | 110 | 44 | 41 | 7 | 74 | 10 | 5 | 34 |
| Over 70 | 178 | 95 | 29 | 30 | 9 | 60 | 17 | 4 | 38 |
| γ-coefficient | 0.18 | 0.23 | 0.06 | 0.13 | 0.24 | 0.30 | 0.09 | 0.53 | |
| P-value | 0.001 | 0.001 | 0.010 | 0.001 | 0.001 | 0.001 | 0.100 | 0.001 | |
|
| |||||||||
| Male | 2849 | 945 | 309 | 446 | 197 | 497 | 68 | 47 | 101 |
| Female | 2267 | 910 | 280 | 427 | 172 | 566 | 93 | 63 | 103 |
| Phi | -0.07 | -0.02 | -0.04 | -0.01 | -0.09 | -0.05 | -0.04 | -0.03 | |
| P-value | 0.001 | 0.095 | 0.003 | 0.100 | 0.001 | 0.001 | 0.005 | 0.070 | |
| Total | 5116 | 1855 | 589 | 873 | 369 | 1063 | 161 | 110 | 204 |
The relationship between death and risk factors among patients with COVID-19
|
|
|
|
|
|
|
|
| Age (year) | 65.2 | 34.6 | 1.09 (1.07, 1.11) | 0.001 | 1.06 (1.04, 1.09) | 0.001 |
| Gender | ||||||
| Female | 19 | 2248 | 1.00 | 1.00 | ||
| Male | 30 | 2819 | 1.26 (0.71, 2.24) | 0.433 | 2.57 (1.28, 5.17) | 0.008 |
| Residence | ||||||
| Rural | 10 | 1027 | 1.00 | 1.00 | ||
| Urban | 39 | 4005 | 1.00 (0.50, 2.01) | 1.000 | 0.71 (0.32, 1.57) | 0.396 |
| Cardiovascular disease | ||||||
| No | 14 | 4769 | 1.00 | 1.00 | ||
| Yes | 32 | 253 | 43.1 (22.7, 81.8) | 0.001 | 4.04 (1.42, 11.53) | 0.009 |
| Hypertension | ||||||
| No | 15 | 4694 | 1.00 | 1.00 | ||
| Yes | 31 | 349 | 27.8 (14.9, 52.0) | 0.001 | 0.99 (0.35, 2.80) | 0.982 |
| Diabetes | ||||||
| No | 30 | 4930 | 1.00 | 1.00 | ||
| Yes | 17 | 111 | 27.8 (14.9, 52.0) | 0.001 | 2.36 (1.02, 5.48) | 0.046 |
| Obesity | ||||||
| No | 37 | 4930 | 1.00 | 1.00 | ||
| Yes | 12 | 72 | 22.2 (11.1, 44.3) | 0.001 | 2.27 (0.84, 6.15) | 0.108 |
| Kidney disease | ||||||
| No | 28 | 4925 | 1.00 | 1.00 | ||
| Yes | 17 | 83 | 36.0 (19.0, 68.4) | 0.001 | 5.86 (2.47, 13.89) | 0.001 |
| Liver disease | ||||||
| No | 39 | 4956 | 1.00 | 1.00 | ||
| Yes | 6 | 55 | 13.90 (5.60, 34.1) | 0.001 | 2.70 (0.71, 10.23) | 0.144 |
| Respiratory disease | ||||||
| No | 28 | 4706 | 1.00 | 1.00 | ||
| Yes | 16 | 214 | 12.6 (6.70, 23.6) | 0.001 | 2.56 (1.11, 5.92) | 0.028 |
a Adjusted odds ratio